PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Blueprint’s Ayvakit fails to best Bayer’s Stivarga

Shares in Blueprint Medicines took a significant hit after it emerged that its Ayvakit (avapritinib) failed to best Bayer’s Stivarga (regorafenib) in patients with gastrointestinal stromal tumours (GIST).

Top-line results from the Phase III VOYAGER study showed that Ayvakit (avapritinib) did not significantly prolong progression-free survival (PFS) versus Stivarga in patients with third- or fourth-line GIST.

US regulators approved Ayvakit in January for adults with unresectable or metastatic GIST harbouring a PDGFR-alpha exon 18 mutation, including PDGFRA D842V mutations, but the firm said based on the data it would not be pursuing further development of the drug in GIST beyond its approved indication.

“We hope these data will reveal important insights to improve the scientific understanding of the disease and inform future innovations in GIST, and we are committed to sharing the results at a future medical meeting,” said Jeff Albers, Blueprint’s chief executive.

The company said it anticipates a decision from the European Commission on its marketing application for the treatment of adults with PDGFRA D842V-mutant GIST in the third quarter.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026